

28 July 2009

IS Pharma plc ('IS Pharma' or the 'Company')

AGM Statement

IS Pharma plc (LSE: ISPH), the international speciality pharmaceutical company, will hold its Annual General Meeting in London this morning.

Geoff McMillan, the Company's Non Executive Chairman, will make the following statement:

"On 3rd June we announced record sales and profits for the year ended 31 March 2009, the most successful year in the Company's history. We have continued to grow revenue and profits from our brands, in particular, from the key promoted brands, Variquel™ (Haemopressin®), Aloxi® and Cryogesic®, both in the UK and internationally. I am pleased to report that trading for the first quarter of the current financial year has been strong and in line with the Board's expectations.

In early June 2009, we announced the launch of Variquel in the UK and since then initial sales have been ahead of the Board's forecasts. Elsewhere across Europe, the roll out of this brand continues on schedule. We also recently announced that this product, which is branded Lucassin® in the USA, has been granted Priority Review by the U.S. Food and Drug Administration.

Aloxi (palonosetron) continues to show strong sales growth. Palonosetron has recently been incorporated into key international guidelines and the ongoing publication of data demonstrates its efficacy in patients receiving various chemotherapy regimes, most recently in those receiving treatments for non-Hodgkin's lymphoma.

Cryogesic, our fast acting analgesic spray, continues to respond well to promotion due to its differential advantages over other existing treatments.

As announced in our Annual Report, having completed two terms of three years each, Peter Murray is to retire as a Non Executive Director at the end of this Annual General Meeting. Peter has been instrumental in the transformation of the Company over recent years and, as an accomplished Non-Executive director, has fulfilled his role to the highest of standards. On behalf of the Board, I would like to thank him for his dedication and support and wish him well in the future.

Our strategy continues to be to generate strong earnings growth from our portfolio of late-stage and launched international pharmaceuticals and medical devices and to pursue the acquisition of new products and corporate opportunities. Implementation of this strategy is underpinned by the Company's strong balance sheet, resulting in IS Pharma being well-positioned for growth. We are confident about the future and look forward to reporting further progress at the time of our interim results in early December."

-End-

For further information, call:

IS Pharma plc

Tel: +44(0) 1244 625150

Tim Wright – CEO / Matthew Hall - CFO

Financial Dynamics Limited Tel: +44(0) 20 7831 3113

Billy Clegg / Edward Westropp

Piper Jaffray Ltd Tel: +44 (0) 20 3142 8700

Neil Mackison / Rupert Winckler

About IS Pharma plc (AIM: ISPH)

IS Pharma (International Speciality Pharmaceuticals) is a fast growing, profitable business which develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.

To find out more please go to www.ispharma.plc.uk

About Variquel™ (terlipressin)

Also branded as Haemopressin® in some European countries and Lucassin® in the US, Variquel is a rapidly acting vasoconstrictor. This specialist injectable is used to manage complications associated with liver disease due to cirrhosis. While liver cirrhosis is commonly associated with alcoholism, it is increasingly being diagnosed as a result of hepatitis and obesity. Variquel is used to treat bleeding oesophageal varices, essentially varicose veins in the gullet which burst and without intervention is life threatening. In the US, Lucassin® is undergoing regulatory review by the U.S. Food and Drug Administration for the treatment of hepatorenal syndrome (HRS) Type 1 and has been granted Priority Review as well as Orphan Drug status and Fast Track designation. The global market for Variquel is estimated at between £50 million - £70 million.

About Aloxi® (palonosetron)

IS Pharma has distribution rights for Aloxi® in the UK. It is a selective 5-HT₃ receptor antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer, with a long half-life of 40 hours and at least 30 times higher receptor binding affinity than currently available compounds. Palonosetron is a second generation 5-HT₃ receptor antagonist, and demonstrates, in clinical trials and clinical practice, a unique long-lasting action in the prevention of CINV. The product has shown to be effective in preventing both acute and delayed CINV in patients receiving moderately emetogenic chemotherapies and acute CINV in patients receiving highly emetogenic chemotherapy.

Palonosetron has been developed by Helsinn Group of Switzerland and today it is marketed as Aloxi®, Onicit®, and Paloxi® in more than 40 countries world-wide. Palonosetron, marketed as Aloxi®, is the leading brand in the USA within the CINV Day of Chemo segment, and it is steadily growing in the European markets.

About Cryogesic®

Cryogesic is a fast-acting vapocoolant spray for topical local analgesia, essentially numbing the area sprayed, prior to minor invasive procedures such as injections. Cryogesic is also used to track the efficacy of epidural blocks.